Genetic Testing in Persons with Age-Related Macular Degeneration and the Use of the AREDS Supplements: To Test or Not to Test?
01/2015
Journal Article
Authors:
Chew, E.Y.;
Klein, M.L.;
Clemons, T.E.;
Agron, E.;
Abecasis, G.R.
Secondary:
Ophthalmology
Volume:
122
Pagination:
212-215
URL:
http://www.ncbi.nlm.nih.gov/pubmed/25456150
Keywords:
Antioxidants; Complement Factor H-human; Complement Factor H/genetics; Dietary Supplements; Genetic Testing; Genotype; Macular Degeneration; Polymorphism-Single Nucleotide; Proteins; Zinc Compounds
Abstract:
The controversy surrounding the use of genetic testing to guide the treatment of persons with age-related macular degeneration (AMD) continues. In 2001, the results of the Age-Related Eye Disease Study (AREDS), a placebo-controlled trial, demonstrated that oral supplementation with a combination of antioxidant vitamins and zinc reduced the risk of progression to late AMD by 25% in persons with intermediate AMD in ≥1 eye.1 Klein et al2 evaluated the influence of the genotypes complement factor H (CFH) (Y402H, rs1061170) and LOC387715/age-related maculopathy susceptibility 2 (ARMS2) (A69S, rs10490924) on the response to treatment with AREDS supplements (combination of antioxidants and zinc), zinc alone, or antioxidants alone in 876 AREDS participants who had available DNA and who were at high risk of developing advanced AMD.
